Insmed’s (INSM) “Buy” Rating Reaffirmed at HC Wainwright

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $90.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 31.73% from the company’s current price.

A number of other equities analysts have also commented on the company. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Monday, September 9th. TD Cowen upped their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Finally, UBS Group upped their target price on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.07.

Insmed Trading Up 1.5 %

Insmed stock opened at $68.32 on Friday. Insmed has a 1 year low of $21.92 and a 1 year high of $80.53. The firm’s 50 day moving average price is $73.03 and its 200-day moving average price is $61.51. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The stock has a market cap of $11.74 billion, a P/E ratio of -12.31 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the prior year, the company posted ($1.10) EPS. The business’s revenue was up 18.1% compared to the same quarter last year. On average, equities analysts predict that Insmed will post -5.42 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the sale, the insider now directly owns 67,856 shares of the company’s stock, valued at $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently modified their holdings of INSM. Vanguard Group Inc. grew its stake in Insmed by 2.7% in the first quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock worth $393,636,000 after purchasing an additional 383,714 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in shares of Insmed in the 2nd quarter worth $237,076,000. Principal Financial Group Inc. grew its position in shares of Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after buying an additional 214,130 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock valued at $110,212,000 after buying an additional 714,539 shares during the period. Finally, Capital International Investors bought a new stake in shares of Insmed in the first quarter valued at about $43,973,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.